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Dirk Kuypers1, Pieter Evenepoel1 and Björn Meijers1,4*Abstract
Background: Serum p-cresyl sulfate (PCS) associates with cardiovascular disease in patients with chronic kidney
disease. PCS concentrations are determined by intestinal uptake of p-cresol, human metabolism to PCS and renal
clearance. Whether intestinal uptake of p-cresol itself is directly associated with cardiovascular disease in patients
with renal dysfunction has not been studied to date.
Methods: We performed a prospective study in patients with chronic kidney disease stage 1 – 5 (NCT00441623).
Intestinal uptake of p-cresol, under steady state conditions, was estimated from 24 h urinary excretion of PCS.
Primary endpoint was time to first cardiovascular event, i.e., cardiac death, myocardial infarction/ischemia,
ventricular arrhythmia, cardiovascular surgery, ischemic stroke or symptomatic peripheral arterial disease. Statistical
analysis was done using Kaplan-Meier estimates and Cox proportional hazard analyses.
Results: In a cohort of 200 patients, median 24 h urinary excretion of PCS amounted to 457.47 μmol (IQR 252.68 –
697.17). After a median follow-up of 52 months, 25 patients reached the primary endpoint (tertile 1/2/3: 5/6/14
events, log rank P 0.037). Higher urinary excretion of PCS was directly associated with cardiovascular events
(univariate hazard ratio per 100 μmol increase: 1.112, P 0.002). In multivariate analysis, urinary excretion of PCS
remained a predictor of cardiovascular events, independent of eGFR (hazard ratio 1.120, P 0.002).
Conclusions: In patients with chronic kidney disease, intestinal uptake of p-cresol associates with cardiovascular
disease independent of renal function. The intestinal generation and absorption of p-cresol may be therapeutic
targets to reduce cardiovascular disease risk in patients with renal dysfunction.
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Chronic kidney disease (CKD) is accompanied by the ac-
cumulation of so-called uremic retention solutes [1].
There is mounting evidence that the colonic microbial
metabolism contributes substantially to these solutes
with p-cresyl sulfate (PCS) being among the most dis-
criminating biomarkers of uremia [2]. PCS has been
linked to cardiovascular disease [3-5], overall mortality
[6,7] and progression of CKD [8].
Serum concentrations of PCS result from the combined
actions of intestinal uptake of p-cresol, metabolism (i.e.,* Correspondence: bjorn.meijers@uzleuven
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unless otherwise stated.sulfate conjugation) to PCS, and eventually, renal excre-
tion of PCS [9]. Renal dysfunction causes PCS to accumu-
late, mainly due to diminished active tubular secretion
[10], and higher serum concentrations of PCS are related
to cardiovascular disease in patients with CKD [3,7]. Until
recently, it was assumed that kidney function was the
main determinant of serum PCS. However, after adjust-
ment for renal function loss, individual serum concentra-
tions of PCS are still widely dispersed [3,7,11]. Intriguingly,
our group identified intestinal uptake of p-cresol to be a
main determinant of this interindividual variability [12].
Total intestinal uptake of p-cresol can be considered a
composite of intestinal generation (i.e., colonic microbial
fermentation of tyrosine) and subsequent intestinal dis-
position, although mechanisms governing both processes
are largely unexplored.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ent of kidney function, is associated with cardiovascular
disease has not been studied to date.
We aimed to explore potential clinical determinants of
the intestinal uptake of p-cresol and to study in depth its
relationship with cardiovascular disease in patients at
different stages of CKD.
Methods
Study population
This is a secondary analysis of the Leuven mild to mod-
erate CKD cohort (clinicaltrials.gov NCT00441623) [3].
Prevalent CKD patients, followed at the nephrology out-
patient clinic of the University Hospitals Leuven, 18 year
of age or older and able to provide consent, were eligible
for inclusion. Patients were screened between November
2005 and September 2006. Data on baseline demograph-
ics were collected at time of informed consent. The
study was performed according to the Declaration of
Helsinki and approved by the ethics committee of the
University Hospitals Leuven. Informed consent was ob-
tained from all patients.
Biochemical measurements
At inclusion, blood was taken by venous puncture for
measurement of hemoglobin (g/dl), albumin (g/l), C-
reactive protein (mg/l), cholesterol (mg/dl), calcium (mg/
dl), phosphate (mg/dl), biointact parathyroid hormone
(PTH) (ng/l), creatinine (mg/dl), blood urea nitrogen (g/
dl) and PCS (μM). Hemoglobin, albumin, C-reactive pro-
tein, cholesterol, calcium, phosphate, biointact PTH, cre-
atinine and blood urea nitrogen were all measured using
standard laboratory techniques. The eGFR was calculated
using the CKD-EPI equation [13]. PCS was quantified
using a dedicated high-performance liquid chromatog-
raphy (HPLC) method as described previously [14]. As-
suming steady state conditions, 24 hour intestinal uptake
of p-cresol was estimated from 24 hour urinary excretion
of PCS. 24 hour urinary collections were sampled when
available at time of inclusion. Completeness was assessed
using 24 hour urinary creatinine excretion. Collections
were considered complete when 24 hour urinary creatin-
ine excretion was within 2 standard deviations of the
mean creatinine excretion for the geographical region of
this study, derived from the INTERSALT study [15]. Pro-
tein intake was calculated according to the formula of
Maroni et al. by using 24 hour urinary urea nitrogen ex-
cretion and body weight [16,17].
Endpoint evaluation
After inclusion, patients were prospectively followed at
the nephrology outpatient clinic at 3- to 6-month inter-
vals until December 31, 2010. Predefined endpoints were
prospectively recorded and coded, blinded from clinicaland biochemical data. The primary endpoint (cardiovas-
cular event during follow-up) was a composite of death
from cardiac causes, non-lethal myocardial infarction,
myocardial ischemia, coronary intervention, ischemic
stroke, or peripheral vascular disease, whichever oc-
curred first. Only one event per subject was included in
the analysis. After review of available information, cause
of death was classified as either cardiovascular, infec-
tious, malignancy, or other. Cardiovascular deaths in-
cluded fatal myocardial infarction, sudden death, and
death due to congestive heart failure. Cases of unob-
served sudden death were considered cardiovascular
death only when other potential causes could be ex-
cluded. Otherwise, they were classified as other cause of
death. Out-of-hospital deaths were coded after consult-
ation of the general practitioner. Non-lethal cardiovascu-
lar events included myocardial infarction, diagnosed
based on elevated levels of cardiac enzymes and/or typ-
ical electrocardiography changes, myocardial ischemia
with typical electrocardiography changes without ele-
vated cardiac enzymes, coronary intervention (thromb-
olysis, percutaneous coronary intervention, or coronary
artery bypass grafting), and ventricular arrhythmia. Is-
chemic stroke was defined as a neurologic deficit lasting
more than 24 hours. Hemorrhagic stroke was excluded
from the primary endpoint. Peripheral vascular disease
included new-onset ischemic pain in the lower limbs,
with abnormal ankle brachial pressure index or radio-
logic evidence of peripheral vascular disease, new-onset
ischemic necrotic lesions, or surgical arterial interven-
tion. Secondary endpoints included overall mortality and
progression of renal disease, defined as progression to
renal replacement therapy and/or doubling of serum
creatinine during follow-up.
Statistical analysis
Data are expressed as mean (standard deviation) for nor-
mally distributed variables or median (interquartile range
(IQR)) for non-normally distributed variables. Differences
between baseline variables according to tertiles of 24 h
urinary excretion of PCS were tested using parametric
ANOVA, Kruskal-Wallis or chi-squared test as appropri-
ate. Correlations between 24 h urinary excretion of PCS
and other variables were calculated by Spearman’s rank
correlation coefficients. To identify independent determi-
nants of 24 h urinary excretion of PCS, multivariate linear
regression analysis was performed. Relevant demographic
(i.e., age, gender, presence of diabetes mellitus, smoking
status, body mass index) and biochemical (i.e., hemoglo-
bin, C-reactive protein (Ln), albumin, eGFR, 24 hour pro-
teinuria (Ln), 24 h protein intake) parameters were first
subjected to a backward elimination procedure on P < 0.2,
with subsequently, a final backward elimination step on
P < 0.05. The Kaplan-Meier method was used to estimate
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test to compare differences between tertiles of 24 h urin-
ary excretion of PCS. Time to first event analysis was per-
formed using Cox proportional hazards analysis. Besides
24 h urinary excretion of PCS, other relevant demographic
(i.e., age, gender, presence of diabetes mellitus, prior car-
diovascular disease, smoking status, body mass index,
systolic blood pressure, use of statin therapy, use of
angiotensin converting enzyme inhitor/receptor blocker
therapy) and biochemical (i.e., hemoglobin, albumin, C-
reactive protein (Ln), cholesterol, calcium, phosphate,
PTH (Ln), creatinine, eGFR, 24 h proteinuria (Ln)) vari-
ables were selected from univariate analysis (P < 0.2). With
this subset of variables different multivariate models wereFigure 1 Patient inclusion, flow chart demonstrating patient screeninbuilt and subjected to backward elimination (P < 0.05).
Due to the limited number of events (n = 25), no more
than three variables (24 h urinary excretion of PCS with
two other variables) were included in each model. To test
the proportionality assumption, each model was tested
against log(time). In case the proportionality assumption
was violated, time-dependent covariates were entered into
the model. For both Kaplan-Meier and Cox proportional
hazard analysis of the primary endpoint, data were cen-
sored at start of renal replacement therapy, death other
than cardiovascular, loss to follow-up, or at the end of the
study observation period. With respect to the secondary
endpoints, data were censored at start of renal replace-
ment therapy (for overall mortality), death (for renalg and inclusion.
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For all statistical analysis, P-values less than 0.05 were
considered significant. All statistical analyses were per-
formed using SAS (version 9.3, the SAS institute, Cary,
NC, USA).
Results
Inclusion and baseline characteristics
Between November 2005 and September 2006, 548 preva-
lent patients with CKD K/DOQI stage 1 – 5, followed at
the nephrology outpatient clinic of the University Hospi-
tals Leuven, Belgium were found eligible to be enrolled in
the Leuven mild to moderate CKD study. 499 patients
providing informed consent were included [3]. Of these,
urinary collections were available for 264 patients and
considered complete for 203 patients. No further follow-
up was scheduled for 3 patients, making a total of 200
patients to be included in the prospective cohort study
(Figure 1). Baseline characteristics of the study population
are presented in Table 1. Glomerular disease was the mostTable 1 Baseline characteristics of study population
Variable Overall (n = 200)
Tertile 1 (
Age (yr) 60 (48–72) 58 (47 –
Gender: male/female (%) 119/81 (59.5/40.5) 34/32 (51
Prior CVD: yes/no (%) 53/147 (26.5/73.5) 13/53 (19
Diabetes: yes/no (%) 31/169 (15.5/84.5) 6/60 (9.1
Current smoker: yes/no (%) 34/166 (17/83) 14/52 (21
Body mass index (kg/m2) 25.67 (22.99 – 28.67) 24.91 (23.31
Systolic blood pressure (mmHg) 132 (120 – 150) 130 (120
Diastolic blood pressure (mmHg) 80 (70 – 85) 80 (70 –
Hemoglobin (g/dl) 13.5 (1.7) 13.5 (1
Albumin (g/l) 45.1 (42.0 – 46.8) 44.8 (41.9
C-reactive protein (mg/l) 2 (1 – 5) 2 (1 –
Cholesterol (mg/dl) 181 (153 – 205) 185 (152
LDL (mg/dl) 83 (66 – 107) 77 (61 –
Calcium (mg/dl) 9.5 (9.3 – 9.9) 9.6 (9.3
Phosphate (mg/dl) 3.4 (2.9 -3.8) 3.3 (2.9
Bicarbonate (mmol/l) 24.6 (2.9) 24.4 (2
Creatinine (mg/dl) 1.82 (1.33 – 2.53) 1.69 (1.13
eGFR (ml/min per 1.73 m2) 33.4 (22.8 – 55.5) 37.9 (24.7
24 hour proteinuria (g) 0.307 (0.108 – 1.128) 0.243 (0.098
Therapy with ACEI/ARB: yes/no (%) 155/45 (22.5/77.5) 53/13 (80
Therapy with statins: yes/no (%) 113/87 (56.5/43.5) 33/33 (5
24 h urinary excretion of PCS (μmol) 457.47 (252.68 – 697.17) 183.76 (51.14
Serum PCS (μM) 46.48 (20.40 – 94.36) 16.91 (5.71
Data are expressed as mean (SD) or median (IQR), as appropriate. Differences betwe
test, as appropriate. CVD, cardiovascular disease; LDL, low-density lipoprotein; eGFR
inhibitor; ARB, angiotensin receptor blocker; PCS, p-cresyl sulfate.prevalent underlying renal disease (37.5%), followed by
undetermined cause (35.5%), vascular disease (9.0%), and
diabetic nephropathy (6.5%). Apart from a small, but sig-
nificant age (median 4 years younger, P 0.01) and systolic
blood pressure (median 3 mmHg lower, P 0.05) difference,
we observed no significant differences between the
current study population and the original patient cohort.
Correlations of 24 h urinary excretion of PCS
24 h urinary excretion of PCS amounted to a median of
457.47 μmol (IQR 252.68 – 697.17). There was a moder-
ate correlation between 24 h urinary excretion of PCS
and serum PCS (Spearman’s rank correlation ρ 0.64, P <
0.0001) (Table 2). In addition, there were significant,
though minor correlations between 24 h urinary excre-
tion of PCS and 24 h intake of protein (ρ 0.30, P <
0.0001) as well as presence of diabetes mellitus (ρ 0.18,
P < 0.0001). Patients with diabetes mellitus had a signifi-
cantly higher 24 h urinary excretion of PCS than pa-
tients without diabetes mellitus (median 668.20 μmol24 h urinary excretion of p-cresyl sulfate P
n = 66) Tertile 2 (n = 67) Tertile 3 (n = 67)
70) 59 (44–72) 64 (50 – 73) 0.15
.5/48.5) 41/26 (61.2/38.8) 44/23 (65.7/34.3) 0.10
.7/80.3) 18/49 (26.9/73.1) 22/45 (32.8/67.2) 0.09
/90.9) 7/60 (10.4/89.6) 18/49 (26.9/73.1) 0.005
.2/78.8) 7/60 (10.4/89.6) 13/54 (19.4/80.6) 0.79
– 29.63) 25.43 (22.65 – 28.60) 26.21 (23.12 – 29.06) 0.80
– 150) 134 (120 – 150) 132 (120 – 150) 0.72
85) 80 (70 – 85) 80 (70 – 85) 0.82
.7) 13.6 (1.8) 13.3 (1.8) 0.44
– 46.3) 45.8 (43.3 – 47.7) 44.8 (41.4 – 46.2) 0.06
6) 1 (1 – 4) 2 (1 – 6) 0.06
– 209) 183 (159 – 200) 166 (151 – 205) 0.35
112) 90 (70 – 113) 81 (66 – 100) 0.23
– 9.9) 9.4 (9.1 – 9.8) 9.5 (9.2 – 9.8) 0.68
– 3.8) 3.4 (2.9 – 4) 3.4 (2.9 – 3.8) 0.88
.9) 24.8 (2.7) 24.5 (3.1) 0.74
– 2.50) 1.86 (1.34 – 2.77) 2.01 (1.42 – 2.4) 0.31
– 61.2) 31.5 (22.8 – 61.0) 32.0 (21.6 – 50.4) 0.44
– 1.128) 0.256 (0.091 – 0.891) 0.429 (0.192 – 1.380) 0.03
.3/19.7) 50/17 (74.6/25.4) 52/15 (77.6/22.4) 0.71
0/50) 36/31 (53.7/46.3) 44/23 (65.7/34.3) 0.07
– 250.03) 454.11 (375.92 - 515.67) 822.02 (694.71 – 1119.62) < 0.0001
– 38.41) 46.57 (26.49-89.60) 79.18 (52.58 –152.34) < 0.0001
en tertiles were tested using parametric ANOVA, Kruskal-Wallis of chi-squared
, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme
Table 2 Spearman’s rank correlation between 24 h urinary
excretion of p-cresyl sulfate and baseline characteristics
Variable ρ P
Age 0.13 0.07
Gender (female vs. male) −0.08 0.25
Prior CVD 0.12 0.09
Diabetes mellitus 0.18 0.009
Current smoker 0.0007 0.99
Body mass index 0.01 0.84
Systolic blood pressure 0.06 0.38
Diastolic blood pressure 0.03 0.64
Hemoglobin −0.07 0.35
Albumin −0.03 0.70
C-reactive protein −0.05 0.47
Cholesterol −0.06 0.43
LDL 0.03 0.68
Calcium −0.03 0.71
Phosphate 0.03 0.65
Parathormone 0.09 0.20
Bicarbonate 0.02 0.82
Creatinine 0.11 0.11
eGFR −0.10 0.15
24 h proteinuria 0.14 0.05
24u protein intake 0.30 < 0.0001
Therapy with ACEI/ARB −0.008 0.91
Therapy with statin 0.13 0.06
Serum PCS 0.64 < 0.0001
CVD, cardiovascular disease; LDL, low-density lipoprotein; eGFR, estimated
glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; PCS, p-cresyl sulfate.
Table 3 Multivariate regression analysis: Factors
associated with 24 h urinary excretion of p-cresyl sulfate
Variable Unit β P
Age year 4.30 0.03
Presence of diabetes mellitus yes vs no 202.67 0.01
Body mass index kg/m2 −19.59 0.003
Hemoglobin g/dl −41.01 0.01
24 h protein intake g 9.21 < 0.0001
Model R2 0.22
Table 4 Cardiovascular events
Events (n = 25) N (%)
Non-fatal 22 (88%)
Cardiac 9 (36%)
New onset angina, conservative 4 (16%)
New onset angina, invasive 3 (12%)
Acute myocardial infarction 1 (4%)
Ventricular arrhythmia 1 (4%)
Ischemic cerebrovascular accident 2 (8%)
Peripheral arterial disease 11 (44%)
Fatal 3 (12%)
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238.37), P 0.009). Although there was a trend of increasing
24u urinary excretion of PCS with higher 24 h proteinuria,
higher age, prior cardiovascular disease, and lower eGFR,
these correlations did not reach significance.
In multivariate analysis, independent determinants of
24 h urinary excretion of PCS were age (β 4.30, P 0.03),
presence of diabetes mellitus (β 202.67, P 0.01), body
mass index (β -19.59, P 0.003), hemoglobin (β - 41.01,
P 0.01) and 24 h protein intake (β 9.21, P < 0.0001)
(Model R2 0.22) (Table 3).
Event analysis
After a median follow-up of 52 months (IQR 20.8 –
57.7), 25 patients reached the combined primary end-
point, including 3 fatal and 22 non-fatal cardiovascular
events (Table 4). Patients were censored at start of renal
replacement therapy (n = 45), death other than cardio-
vascular (n = 15), loss to follow-up (n = 21), and at the
end of the study observation period. Cumulativeincidence of the primary endpoint in tertiles of urinary
excretion of PCS was estimated with the Kaplan-Meier
method (Figure 2). Log rank test was significant for dif-
ferences between these 3 groups (P 0.037). In univariate
Cox proportional hazard analysis, 24 h urinary excretion
of PCS was directly associated with cardiovascular dis-
ease during follow-up (Hazard ratio (HR) per 100 μmol
increase 1.112, P 0.002, HR highest vs. lowest tertile
3.011, P 0.03). Other significant variables include age
(HR 1.064, P 0.002), systolic blood pressure (HR 1.021,
P 0.04), prior cardiovascular disease (HR 5.880, P <
0.0001), presence of diabetes mellitus (HR 4.420, P 0.0003),
albumin (HR 0.872, P 0.0003), eGFR (HR 0.973, P 0.02),
24 h proteinuria (Ln) (HR 1.298, P 0.009). We then built
different multivariate models, each consisting of 3 vari-
ables (24 h urinary excretion of PCS and 2 other variables)
(Table 5). In each model 24 h urinary excretion of PCS
remained a significant predictor of cardiovascular events
during follow-up. We also built sequential models with
addition of variables that were considered confounders a
priori, i.e., age, presence of diabetes mellitus, protein in-
take and eGFR. Again, 24 h urinary excretion of PCS
remained associated with cardiovascular events during
follow-up (HR 1.103 (1.006 – 1.209), P 0.04).
We also explored the relationship between 24 h urin-
ary excretion of PCS and overall mortality, as well as
renal disease progression. In this cohort, we observed a
total of 21 deaths (5 cardiovascular, 7 oncologic, 1 infec-
tious and 8 other deaths), again censored at start of renal
Figure 2 Kaplan-Meier curve of time to first cardiovascular
event. Tertiles of 24 h urinary excretion of p-cresyl sulfate. Tertile 1
to 3: 5, 6 and 14 events, respectively. Log rank test P 0.037.
Table 6 Cox proportional hazard multivariate models of
time to death (number of events = 21)
Model 24 h urinary excretion of p-cresyl sulfate
Hazard ratio per 100 μmol increase
(95% confidence interval)
P
1. Unadjusted 1.090 (1.015 – 1.169) 0.02
2. Age and diabetes
mellitus
1.102 (1.015 – 1.198) 0.02
3. eGFR and albumine 1.090 (1.004 – 1.182) 0.04
4. Systolic blood pressure
and gender
1.082 (1.010 – 1.158) 0.03
5. Hemoglobin and
C-reactive protein (Ln)
1.083 (1.005 – 1.167) 0.04
6. Calcium and
parathormone (Ln)
1.092 (1.009 – 1.182) 0.03
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Cox proportional hazard analysis, 24 h urinary excretion
of PCS was directly associated with overall mortality
(HR per 100 μmol increase 1.090, P 0.02). Other signifi-
cant variables include age (HR 1.072, P 0.0003), diabetes
mellitus (HR 4.011, P 0.002), eGFR (HR 0.966, P 0.01),
systolic blood pressure (HR 1.025, P 0.02), hemoglobin
(HR 0.743, P 0.02), C-reactive protein (Ln) (HR 1.532,
P 0.02) and PTH (Ln) (HR 1.680, P 0.01). In addition,
we built different multivariate models with 24 h urinary
excretion of PCS remaining a significant determinant of
overall mortality in all trivariate-adjusted models (Table 6).
As for cardiovascular disease, we also built sequential
models with addition of variables that were considered
confounders a priori, i.e., age, presence of diabetes melli-
tus, protein intake and eGFR. Again, there was a clear,Table 5 Cox proportional hazard multivariate models of
time to first cardiovascular event (number of events = 25)
Model 24 h urinary excretion of p-cresyl sulfate
Hazard ratio per 100 μmol increase
(95% confidence interval)
P
1. Unadjusted 1.112 (1.041 – 1.187) 0.002
2. Prior cardiovascular
disease and diabetes
mellitus
1.083 (1.005 – 1.167) 0.04
3. eGFR and 24 h
proteinuria (Ln)
1.120 (1.042 – 1.205) 0.002
4. Creatinine and age 1.120 (1.040 – 1.206) 0.003
5. Albumine and body
mass index
1.078 (1.014 – 1.146) 0.02
6. Systolic blood pressure
and parathormone (Ln)
1.106 (1.038 – 1.179) 0.002
7. Hemoglobin and C-
reactive protein (Ln)*
1.112 (1.041 – 1.187) 0.002
*Hemoglobin was entered as time-dependent covariate.albeit non-significant, relationship between 24 h urinary
excretion of PCS and overall mortality (HR 1.098 (0.987 –
1.222), P 0.09).
Progression of renal disease was observed in 55 pa-
tients during follow-up. However, there was no associ-
ation between 24 h urinary excretion of PCS and renal
disease progression (P 0.19).
Discussion
We studied the clinical determinants of intestinal uptake
of p-cresol in a cohort of patients with different stages
of CKD, and explored its relationship with cardiovascu-
lar disease, overall mortality and renal disease progres-
sion. Assuming steady state conditions, 24 h urinary
excretion of PCS was used to estimate intestinal uptake
of p-cresol. The key findings are as follows: (i) intestinal
uptake of p-cresol is highly variable in CKD patients,
although factors determining this interindividual vari-
ability remain largely unknown; (ii) intestinal uptake of
p-cresol is associated with cardiovascular disease and
overall mortality during follow-up, but not with renal
disease progression.
Serum PCS has been linked to cardiovascular disease
[3-5], overall mortality [6,7] and progression of CKD [8].
Intriguingly, there is a wide dispersion of individual
serum concentrations of PCS in CKD patients, even
after adjustment for renal function loss [3,7,11]. Re-
cently, our group identified intestinal uptake of p-cresol
to be a main determinant of this interindividual variabil-
ity [12]. Therefore, we hypothesized that intestinal up-
take of p-cresol, in addition to diminished clearance of
PCS due to renal failure, is directly associated with ad-
verse outcomes in CKD.
In this cohort we observed a direct relationship be-
tween intestinal uptake of p-cresol and cardiovascular
disease during follow-up, as well as overall mortality.
These associations remained significant after adjustment
for several risk factors, including markers of renal (dys)
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as a unique and important contributor to adverse out-
comes in patients with CKD, demonstrating the com-
plexity of the gut-kidney axis [18].
As it was already demonstrated that serum PCS was
related to CKD progression [8], we hypothesized that in-
testinal uptake of p-cresol, as a marker for the renal
tubular load of PCS, was also an independent determin-
ant of renal function deterioration. At odds with the
findings of Wu et al., we were not able to demonstrate an
association between intestinal uptake of p-cresol and renal
disease progression. This questions the true relevance of
PCS in the pathogenesis of CKD progression, especially as
serum PCS was neither related to CKD progression in our
original cohort (unpublished data), nor are we aware of
clinical data confirming this association in another patient
group. We can, however, not exclude the possible impact
of genetic or environmental differences as our cohort
mainly consists of Caucasian patients in contrast to the
Asian patient group studied by Wu et al. [8].
As intestinal uptake of p-cresol appeared highly vari-
able, we explored factors determining this interindividual
variability. Protein intake was the most significant deter-
minant of intestinal uptake of p-cresol. Age, body mass
index and hemoglobin were other determining factors.
Presence of diabetes mellitus was also independently as-
sociated with higher intestinal uptake of p-cresol, which
confirms and extends previous observations of a rela-
tionship between higher serum concentrations of PCS
and diabetes mellitus [4,19].
However, it must be noted that most of variability of
intestinal uptake of p-cresol could not be explained by
standard demographic and biochemical variables (model
R2 0.22). Intestinal uptake of p-cresol is a composite of
its intestinal generation and intestinal disposition. Intes-
tinal generation of p-cresol depends on colonic micro-
bial fermentation of tyrosine. Factors governing this
fermentation process are still largely unknown. It is as-
sumed that an important regulator of bacterial metabol-
ism is substrate availability, especially the ratio of
available fermentable carbohydrate to nitrogen (protein)
[20,21]. Accordingly, protein intake was a main deter-
minant of intestinal uptake of p-cresol in our study [22].
In addition, it is suggested that CKD goes along with a
different microbial composition [23]. Therefore, CKD
might also have an impact on the microbial metabolism
as such, but this needs further examination.
Intestinal disposition of p-cresol is the second factor
determining intestinal uptake of p-cresol. Pharmacokin-
etics of p-cresol in health and renal disease remain to be
elucidated, as are possible interindividual differences in
intestinal p-cresol disposition.
There are limitations to our study. First, we estimated
total intestinal uptake of p-cresol by 24 h urinaryexcretion of PCS, thus assuming negligible non-renal
clearance of serum PCS and minor conjugation to other
metabolites (i.e., p-cresyl glucuronide). Second, due to
the relatively low number of events, full multivariate ad-
justment was not possible. To overcome this limitation,
we have built multiple trivariate models, consistently
demonstrating the predictive performance of intestinal
uptake of p-cresol. Third, our study population mainly
consists of patients of Caucasian origin. Care must be
taken to extrapolate our data to other patient popula-
tions. Finally, assessment of completeness of urinary col-
lections is arbitrary. We assumed completeness of
urinary collections when urinary excretion of creatinine
was within 2 standard deviations of the mean creatinine
excretion for the geographical region of this study
(INTERSALT study [15]).
Conclusions
Intestinal uptake of p-cresol demonstrates substantial in-
terindividual variability, but associates with cardiovascular
disease and overall mortality in patients with CKD. In-
sights into mechanisms governing intestinal generation
and absorption of p-cresol may lead to identification of
novel therapeutic targets to reduce cardiovascular disease
and overall mortality in CKD.
Abbreviations
CKD: Chronic kidney disease; PCS: p-cresyl sulfate; PTH: Parathyroid hormone;
HR: Hazard ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RP conceived of the study, collected and interpreted the data, performed the
statistical analysis, and drafted the manuscript. LV collected and interpreted the
data, and helped to draft the manuscript. KV interpreted the data, and revised
the manuscript. PA interpreted the data, and revised the manuscript. BB
collected and interpreted the data, and revised the manuscript. KC collected
and interpreted the data, and revised the manuscript. DK collected and
interpreted the data, and revised the manuscript. PE collected and interpreted
the data, and helped to draft the manuscript. BM conceived of the study,
collected and interpreted the data, performed the statistical analysis, and
drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgements
RP is the recipient of a Ph.D. fellowship of the Research Foundation -
Flanders (FWO) (grant 11E9813N). The funding body had no involvement in
study design, in collection, analysis and interpretation of data, in writing of
the manuscript, or in the decision to submit the manuscript for publication.
Part of this work was presented at the American Society of Nephrology Kidney
Week, November 5 through November 10, 2013, Atlanta, GA. Technical
assistance by H. De Loor, M. Dekens and T. Coopmans is highly appreciated.
Author details
1Department of Microbiology and Immunology, Division of Nephrology,
University Hospitals Leuven, B-3000, Leuven, Belgium. 2Translational Research
for Gastrointestinal Disorders (Targid) and Leuven Food Science and
Nutrition Research Centre (LFoRCe), University of Leuven, B-3000 Leuven,
Belgium. 3Department of Pharmaceutical and Pharmacological Sciences,
Drug Delivery and Disposition, University of Leuven, B-3000 Leuven, Belgium.
4Division of Internal Medicine, Department of Nephrology, University
Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Poesen et al. BMC Nephrology 2014, 15:87 Page 8 of 8
http://www.biomedcentral.com/1471-2369/15/87Received: 5 December 2013 Accepted: 5 June 2014
Published: 9 June 2014References
1. Rhee EP, Thadhani R: New insights into uremia-induced alterations in
metabolic pathways. Curr Opin Nephrol Hypertens 2011, 20:593–598.
2. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer
TW: Colonic contribution to uremic solutes. J Am Soc Nephrol 2011,
22:1769–1776.
3. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D,
Vanrenterghem Y, Evenepoel P: p-Cresol and cardiovascular risk in mild-
to-moderate kidney disease. Clin J Am Soc Nephrol 2010, 5:1182–1189.
4. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel
P: Free p-cresol is associated with cardiovascular disease in hemodialysis
patients. Kidney Int 2008, 73:1174–1180.
5. Shafi T, Meyer TW, Hostetter TH, Melamed ML, Liu Y, Banerjee T, Powe NR:
Serum Levels of Free Retained Organic Solutes and Outcomes in
Hemodialysis Patients [Abstract]. ASN Kidney Week 2013, 2013:2013.
6. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free
serum concentrations of the protein-bound retention solute p-cresol
predict mortality in hemodialysis patients. Kidney Int 2006, 69:1081–1087.
7. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar
M, Choukroun G, Vanholder R, Massy ZA: Free p-cresylsulphate is a
predictor of mortality in patients at different stages of chronic kidney
disease. Nephrol Dial Transplant 2010, 25:1183–1191.
8. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY,
Wu MS: p-Cresyl sulphate and indoxyl sulphate predict progression of
chronic kidney disease. Nephrol Dial Transplant 2011, 26:938–947.
9. Meyer TW, Hostetter TH: Uremic solutes from colon microbes. Kidney Int
2012, 81:949–954.
10. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y:
Characterization of uremic toxin transport by organic anion transporters
in the kidney. Kidney Int 2004, 65:162–174.
11. Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke
F, Glorieux G, Choukroun G, Massy Z, Vanholder R: Estimated glomerular
filtration rate is a poor predictor of concentration for a broad range of
uremic toxins. Clin J Am Soc Nephrol 2011, 6:1266–1273.
12. Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, Naesens
M, Vanrenterghem Y, Kuypers D, Evenepoel P, Meijers B: Renal Clearance
and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD.
Clin J Am Soc Nephrol 2013, 8:1508–1514.
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI,
Kusek JW, Eggers P, Van LF, Greene T, Coresh J: A new equation to
estimate glomerular filtration rate. Ann Intern Med 2009, 150:604–612.
14. de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W,
Evenepoel P: Sodium octanoate to reverse indoxyl sulfate and p-cresyl
sulfate albumin binding in uremic and normal serum during sample
preparation followed by fluorescence liquid chromatography.
J Chromatogr A 2009, 1216:4684–4688.
15. Intersalt: an international study of electrolyte excretion and blood
pressure. Results for 24 hour urinary sodium and potassium excretion.
Intersalt Cooperative Research Group. BMJ 1988, 297:319–328.
16. Masud T, Manatunga A, Cotsonis G, Mitch WE: The precision of estimating
protein intake of patients with chronic renal failure. Kidney Int 2002,
62:1750–1756.
17. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen
intake of patients with chronic renal failure. Kidney Int 1985, 27:58–65.
18. Meijers BK, Evenepoel P: The gut-kidney axis: indoxyl sulfate, p-cresyl
sulfate and CKD progression. Nephrol Dial Transplant 2011, 26:759–761.
19. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z,
Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D, Soulage CO:
p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am
Soc Nephrol 2013, 24:88–99.
20. Birkett A, Muir J, Phillips J, Jones G, O’Dea K: Resistant starch lowers fecal
concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996,
63:766–772.
21. Smith EA, Macfarlane GT: Enumeration of human colonic bacteria
producing phenolic and indolic compounds: effects of pH, carbohydrate
availability and retention time on dissimilatory aromatic amino acid
metabolism. J Appl Bacteriol 1996, 81:288–302.22. Geypens B, Claus D, Evenepoel P, Hiele M, Maes B, Peeters M, Rutgeerts P,
Ghoos Y: Influence of dietary protein supplements on the formation of
bacterial metabolites in the colon. Gut 1997, 41:70–76.
23. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, Desantis TZ, Ni Z, Nguyen TH,
Andersen GL: Chronic kidney disease alters intestinal microbial flora.
Kidney Int 2013, 83:308–315.
doi:10.1186/1471-2369-15-87
Cite this article as: Poesen et al.: Cardiovascular disease relates to
intestinal uptake of p-cresol in patients with chronic kidney disease.
BMC Nephrology 2014 15:87.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
